The pursuit of excelMedal_4mpix__MG_0199-150x150lence in biopharmaceutical innovation in Russia has never had a sponsor-until now. Prix Galien International, a global network of Nobel laureates in medicines, established its 18th country beachhead in Moscow earlier this year, culminating in a historic first: an October 24 awards dinner to recognize the best in new drug research as well as innovation in biotechnology and pharmaceutical products.
Dr. Jan Lundberg, EVP science and technology and president Lilly Research Labs, Lilly & Co., sits down to discuss the company?s new approach to drug development and its Phase III pipeline.
The European Commission mandated that all member states have a plan for rare diseases back in June 2009. With the EC deadline just weeks away, the UK has now finalized its own.
For senior executives, meeting the requirements of a Consent Decree to the satisfaction of regulators is only half of the job.
So, we’ve experienced two months of Obamacare. How is the U.S. pharmaceutical industry doing with this new program? I spent two weeks getting the opinions of several Rx representatives on their experience with Obamacare, as well as their thoughts on how it is impacting their marketing, sales, and R&D planning for 2014 and beyond.
The bacterial meningitis outbreak at Princeton University in recent weeks has raised questions about why there is no vaccine in US to prevent this deadly disease, when such a therapy is approved in Europe and Australia.
New and emerging technologies are noteworthy not simply for the excellent science behind them but also for the way they expose those raw edges of the industry’s business model. In biopharma today, disruptive changes to the model are being driven by two forces.
The annual worldwide antibiotic awareness event - celebrated in Europe on November 15 - generated some alarming statistics, some reassuring statements from official sources, and some expressions of urgency from drug developers
The pharmaceutical sector needs to shape up to deal with the big uptake in bribery and corruption enforcement actions - and not just in the USA, write Toby Duthie and David Lawler.
Poorer people are being prescribed more expensive branded drugs. Is that bad? According to a new investigation it is. And it is costing the taxpayers a shovel-load of money. Furthermore, it’s unnecessary.
There has been a lot of talk lately that ‘Big Data’ is just BS. Peter Houston looks beyond the hype to reveal what companies should be focusing on.
The radical shift currently taking place in pharma marketing is all about partnering with patients rather than talking at them
“Leaning in” might be all the rage – but “hanging in” is just as important to make sure women gather momentum in the workplace. At a meeting of the Global Women in Business Advisory Council last week in Palm Springs, CA, members discussed ways to build critical mass for stronger female participation in the workplace.
Compared to other manufacturing and technology industries, the bio/pharmaceutical industry has one of the longest product development timelines.
Congress gave final approval this week to new legislation to strengthen Food and Drug Administration authority to oversee large pharmacy compounders of sterile injectibles and to require more comprehensive tracking of prescription drugs moving through the global supply chain.
As digital becomes a greater part of the pharma marketing mainstream, can the sector attract the digital marketing talent it needs to succeed in the space? That’s a question pondered this week by Rich Meyer on his World of DTC Marketing blog.
Big Pharma is quietly stepping up to provide critical supplies of essential medicines, other health equipment, and skilled local personnel to areas of the Philippines devastated by Typhoon Haiyan this month. Although industry operations in the Philippines appear largely intact, most companies are working through global humanitarian aid organizations due to the logistical challenges created by the collapse of infrastructure on the ground.
Oncology-market access doesn’t “just happen” anymore. As competition in the U.S. health-care market only continues to intensify, oncology-drug companies will need a good corporate strategy to ensure physician uptake and payer coverage of therapies.
At last week’s Partnering for Cures conference held in New York City, several expert panels discussed new angles of approaching solutions to disease, encouraging investment and mitigating inefficiencies in the delivery of medicines within the current healthcare system.
The future of healthcare centers on scale, population health and the value of care rather than the volume of care, according to thought leaders speaking at a leadership briefing in November in Akron, Ohio. But the political atmosphere also adds layers of complexity, they say.
FDA is proposing to revise its rules to permit generic drug manufacturers to initiate safety labeling changes, and not wait until the brand company takes that action.
Health plans that limit drug converge will encourage consumers to obtain medicines illegally, according to pharmacy experts.
Orphan drugs were given short shrift in PharmExec’s 2014 Pipeline Report, but a couple of pipeline candidates targeting small populations did make the list, and are expected to earn big dollars in the next few years.
In the early 1990’s, during the debate over the Clinton healthcare plan, I recall sitting in an interesting meeting at my pharma company headquarters.
Long awaited details have been announced in the Heads of Agreement for the latest Pharmaceutical Price Regulation Scheme (PPRS). It’s worth a read in full (and you can find it here) but some highlights are set out here.
A Twitter (TWTR) IPO is imminent and looks likely to cement the social network’s future - good news for pharma marketers that increasingly see the network as an important place to engage HCPs and the public.
Pharm Exec's two key features this month illustrate the strategic contradiction facing today's industry.
April might be – as T S Eliot suggested – the cruellest month, but for pharmaceuticals in Europe, October was certainly a contender to win an award as the busiest one.
The implosion of the Affordable Care Act’s vaunted healthcare.gov benefit enrollment process has obscured a far more critical issue for Big Pharma: how much leeway do companies have in promoting durable brand affiliations among the potentially millions of new patients with subsidized access to new medicines?
